Last updated: 08/05/2021 05:10:08
Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relief From Dentine Hypersensitivity
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief from Dentinal Hypersensitivity
Trial description: This will be a single centre, two week, randomised, examiner blind, two treatment arm, parallel design, stratified (by maximum baseline Schiff sensitivity score of the two selected test teeth), controlled study, in participant with at least two sensitive teeth that meet the study criteria at the Screening and Baseline visits. The study will be conducted in participants in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity at screening.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Change From Baseline in Schiff Sensitivity Score at Day 14
Timeframe: Baseline, Day 14
Secondary outcomes:
Change From Baseline in Schiff Sensitivity Score at Day 7
Timeframe: Baseline, Day 7
Change From Baseline in Tactile Threshold at Day 7 and Day 14
Timeframe: Baseline, Day 7 and Day 14
Interventions:
Other: Stannous Fluoride Dentifrice
Other: Sodium monofluorophosphate Dentifrice
Enrollment:
143
Observational study model:
Not applicable
Primary completion date:
2016-11-03
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Dentin Sensitivity
Product
SKF46655, SKF46656, sodium fluoride
Collaborators
Not applicable
Study date(s)
January 2016 to March 2016
Type
Interventional
Phase
4
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
Yes
- Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written
- informed consent and has received a signed and dated copy of the informed consent form.
- Women who are breast-feeding, known to be pregnant or who are intending to become pregnant over the duration of the study.
- Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated
Inclusion and exclusion criteria
Inclusion criteria:
- Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Aged 18-65 years inclusive.
- Good general and mental health with: No clinically significant and relevant abnormalities of medical history or oral examination. Absence of any condition that would impact on the participant’s safety or wellbeing or affect the individual’s ability to understand and follow study procedures and requirements.
- Self-reported history of dentinal hypersensitivity (DH) lasting more than six months but not more than 10 years.
- Minimum of 20 natural teeth.
- Minimum of 2 accessible non-adjacent teeth (incisors, canines, pre-molars), preferably in different quadrants, that meet all of the following criteria at screening: Signs of facial/cervical gingival recession and/or signs of erosion or abrasion (EAR). Tooth with MGI score =0 adjacent to the test area (exposed dentine) only and a clinical mobility of ≤1. Tooth with signs of sensitivity measured by qualifying evaporative air assessment (yes[Y]/No[N] response).
- Minimum of two, non-adjacent accessible teeth (incisors, canines, pre-molars), that meet all of the following criteria at screening: Tooth with signs of sensitivity, measured by response to a qualifying tactile stimulus (Yeaple ≤ 20g) and evaporative air assessment (Schiff sensitivity score ≥ 2).
Exclusion criteria:
- Women who are breast-feeding, known to be pregnant or who are intending to become pregnant over the duration of the study.
- Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
- Previous participation in this study or participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit.
- Recent history (within the last year) of alcohol or other substance abuse.
- Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes or causing xerostomia.
- Dental prophylaxis within 4 weeks of Screening.
- Tongue or lip piercing or presence of dental implants.
- Gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of Screening, scaling or root planning within 3 months of Screening.
- Teeth bleaching within 8 weeks of Screening.
- Tooth with evidence of current or recent caries, or reported treatment of decay within 12 months of Screening.
- Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine.
- Sensitive tooth not expected to respond to treatment with an over-the-counter dentifrice.
- Use of an oral care product indicated for the relief of dentine hypersensitivity within 8 weeks of screening.
- Daily doses of medication/treatments which, in the opinion of the investigator, could interfere with the perception of pain. Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilisers, anti-depressants, mood-altering and anti-inflammatory drugs.
- Currently taking antibiotics or has taken antibiotics within 2 weeks of Baseline.
- Daily dose of a medication which, in the opinion of the Investigator, is causing xerostomia.
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2016-11-03
Actual study completion date
2016-11-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website